The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: Final report of CCOG-0902 study.
Naomi Hayashi
No relevant relationships to disclose
Goro Nakayama
No relevant relationships to disclose
Kiyoshi Ishigure
No relevant relationships to disclose
Hiroyuki Yokoyama
No relevant relationships to disclose
Toyohisa Yaguchi
No relevant relationships to disclose
Hiroshi Kojima
No relevant relationships to disclose
Kenji Tsuboi
No relevant relationships to disclose
Akihiro Ito
No relevant relationships to disclose
Tomohiro Deguchi
No relevant relationships to disclose
Masanori Sekiya
No relevant relationships to disclose
Chie Tanaka
No relevant relationships to disclose
Keisuke Uehara
No relevant relationships to disclose
Yuichi Ando
No relevant relationships to disclose
Yasuhiro Kodera
No relevant relationships to disclose